Catatonie < Catechol O-methyltransferase < Catechol methyltransferase

Facettes :

List of bibliographic references indexed by Catechol O-methyltransferase

Number of relevant bibliographic references: 18.

Ident.	Authors (with country if any)	Title
001178 (2012)	Lonneke M. L. De Lau [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Peter Heutink [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas]	Catechol-O-methyltransferase Val158Met and the Risk of Dyskinesias in Parkinson's Disease
001E11 (2010)	Jeroen Hoogland [Pays-Bas] ; Rob M. A. De Bie [Pays-Bas] ; Caroline H. Williams-Gray [Royaume-Uni] ; Dino Muslimovi [Pays-Bas] ; Ben Schmand [Pays-Bas] ; Bart Post [Pays-Bas]	Catechol‐O‐methyltransferase val158met and cognitive function in Parkinson's disease
003379 (2006)	Thomas Müller [Allemagne] ; Christoph Erdmann [Allemagne] ; Siegfried Muhlack [Allemagne] ; Dirk Bremen [Allemagne] ; Horst Przuntek [Allemagne] ; Dirk Woitalla [Allemagne]	Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels
003908 (2005)	Manuela Contin [Italie] ; Paolo Martinelli [Italie] ; Mirella Mochi [Italie] ; Roberto Riva [Italie] ; Fiorenzo Albani [Italie] ; Agostino Baruzzi [Italie]	Genetic polymorphism of catechol‐O‐methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's disease
003A17 (2005)	Richard Camicioli [Canada] ; Ali Rajput [Canada] ; Michelle Rajput [Canada] ; Christian Reece [Canada] ; Haydeh Payami [États-Unis] ; Chunhai Hao [Canada] ; Alex Rajput [Canada]	Apolipoprotein E ϵ4 and catechol‐O‐methyltransferase alleles in autopsy‐proven Parkinson's disease: Relationship to dementia and hallucinations
004474 (2002)	Alexander Fisher [Australie] ; James Croft-Baker [Australie] ; Michael Davis [Australie] ; Patrick Purcell [Australie] ; Allan J. Mclean [Australie]	Entacapone‐Induced Hepatotoxicity and Hepatic Dysfunction
004548 (2002)	John L. Goudreau [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Matthew J. Farrer [États-Unis] ; Timothy G. Lesnick [États-Unis] ; Andrew B. Singleton [États-Unis] ; James H. Bower [États-Unis] ; John A. Hardy [États-Unis] ; Walter A. Rocca [États-Unis]	Case‐Control study of dopamine transporter‐1, monoamine oxidase‐B, and catechol‐O‐methyl transferase polymorphisms in Parkinson's disease
004637 (2002)		COMT inhibitors
004707 (2001)	William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie]	Randomized trial of tolcapone versus pergolide as add‐on to levodopa therapy in Parkinson's disease patients with motor fluctuations
004A31 (2000)	Ikuko Mizuta [Japon] ; Eiji Mizuta [Japon] ; Shunzou Yamasaki [Japon] ; Sadako Kuno [Japon] ; Minoru Yasuda [Japon] ; Chikako Tanaka [Japon]	Meta‐analysis of polymorphism of the catechol‐O‐methyltransferase gene in relation to the etiology of Parkinson's disease in Japan
004A56 (2000)	Mickie D. Welsh [États-Unis] ; Ernest Dorflinger [États-Unis] ; Doris Chernik [États-Unis] ; Cheryl Waters [États-Unis]	Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone
004E53 (1999)		Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients
005093 (1998)	Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; Heidi Shale [États-Unis] ; Simon Pedder [États-Unis] ; Ernest E. Dorflinger [États-Unis]	A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
005355 (1997)	Lance A. Smith ; Ariel Gordin ; Jenner [Finlande] ; C. David Marsden [Royaume-Uni]	Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets
005443 (1997)	E. Dupont [Danemark] ; J.-M. Burgunder [Suisse] ; L. J. Findley [Royaume-Uni] ; J.-E. Olsson [Suède] ; E. Dorflinger [États-Unis]	Tolcapone added to levodopa in stable parkinsonian patients : A double-blind placebo-controlled study
005462 (1997)	J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; S. Ahtila [Finlande] ; P. Tuomainen [Finlande] ; H. Ter V Inen [Finlande]	Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease
005501 (1997)	T. Xie [Hong Kong] ; S. L. Ho [Hong Kong] ; L. S. W. Li [Hong Kong] ; O. C. K. Ma [Hong Kong]	G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease
005A18 (1995)	T. L. Davis [États-Unis] ; M. Roznoski ; R. S. Burns	Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenalalanine/carbidopa and selegiline

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i -k "Catechol O-methyltransferase" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i  \
                -Sk "Catechol O-methyltransferase" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Catechol O-methyltransferase
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024